Literature DB >> 12789293

Angiogenesis, lymphangiogenesis, and melanoma metastasis.

Michael Streit1, Michael Detmar.   

Abstract

The induction of angiogenesis is a critical point in the development of most human tumors - including melanomas. Some of the earliest studies in the field of tumor angiogenesis showed that transplantation of human melanoma fragments into the hamster cheek pouch stimulated blood vessel growth. Since then, numerous studies have demonstrated that human melanomas also induce angiogenesis. The prognostic importance of the degree of melanoma vascularization, however, has remained controversial. Elevated expression of several angiogenic factors, including vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8, has been detected in primary cutaneous melanomas, and the importance of these mediators in promoting melanoma angiogenesis and metastasis has been confirmed in tumor xenotransplant models. Based upon these findings, several clinical trials of angiogenesis inhibitors have been initiated in human melanoma patients and are currently underway. Recent experimental evidence indicates that tumor-associated lymphangiogenesis also plays an important role in mediating tumor spread to regional lymph nodes. These observations have important implications for prognosis and treatment of human melanomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12789293     DOI: 10.1038/sj.onc.1206457

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  62 in total

Review 1.  Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

Authors:  József Tímár; Balázs Gyorffy; Erzsébet Rásó
Journal:  Clin Exp Metastasis       Date:  2010-02-24       Impact factor: 5.150

2.  Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues.

Authors:  Shao-Hua Peng; Hong Deng; Jian-Feng Yang; Ping-Ping Xie; Cheng Li; Hao Li; De-Yun Feng
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

3.  Tumor cell transendothelial passage in the absorbing lymphatic vessel of transgenic adenocarcinoma mouse prostate.

Authors:  Giacomo Azzali
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 4.  Pericytes: gatekeepers in tumour cell metastasis?

Authors:  Holger Gerhardt; Henrik Semb
Journal:  J Mol Med (Berl)       Date:  2007-09-22       Impact factor: 4.599

5.  Angiogenesis and melanoma - from basic science to clinical trials.

Authors:  Maxine Sylvia Emmett; Daemon Dewing; Rowan Oliver Pritchard-Jones
Journal:  Am J Cancer Res       Date:  2011-08-08       Impact factor: 6.166

6.  Targeting angiogenesis in melanoma: prospects for the future.

Authors:  P G Corrie; B Basu; K Ahmad Zaki
Journal:  Ther Adv Med Oncol       Date:  2010-11       Impact factor: 8.168

7.  Characterization of Angiogenesis and Lymphangiogenesis in Human Minor Salivary Glands with Sjögren's Syndrome.

Authors:  Andrew D McCall; Olga J Baker
Journal:  J Histochem Cytochem       Date:  2015-01-30       Impact factor: 2.479

8.  A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.

Authors:  Elena Kurenova; Deniz Ucar; Jianqun Liao; Michael Yemma; Priyanka Gogate; Wiam Bshara; Ulas Sunar; Mukund Seshadri; Steven N Hochwald; William G Cance
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Phase II trial of vorinostat in advanced melanoma.

Authors:  N B Haas; I Quirt; S Hotte; E McWhirter; R Polintan; S Litwin; P D Adams; T McBryan; L Wang; L P Martin; M vonMehren; R K Alpaugh; J Zweibel; A Oza
Journal:  Invest New Drugs       Date:  2014-01-25       Impact factor: 3.850

10.  Tumour-associated lymphangiogenesis in conjunctival malignant melanoma.

Authors:  P Zimmermann; T Dietrich; F Bock; F K Horn; C Hofmann-Rummelt; F E Kruse; C Cursiefen
Journal:  Br J Ophthalmol       Date:  2009-07-23       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.